We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/10/2020 11:26 | I would think 2bn bucks mkt cap is a pretty fair target. Perhaps 12mths away if progress continues as it has to date. Saying that, if they partner blautix, pick up another Merck type partner on oncology, prove Mrx5 is efficacious on as a mono therapy, and have a covid win with mrx4 we may need to revise our targets significantly higher. This would be a major league disruptive tech that on Nasdaq would demand a stratospheric valuation, double figure billions not unrealistic in a few years. | mr roper | |
24/10/2020 11:22 | Kangaman I'm putting together a little spreadsheet to keep on top of the arbitrage opportunity Will put it up later | the stigologist | |
24/10/2020 11:17 | Though they have given 13% of company @ £1.10, a rock bottom price, the positives are clear: 1. The near term funding issues are over, as it secures funds till 3Q 2021. This is long time in the case of 4D as so much is in the pipeline to come through in the next 12 months, least of all substantial payment from Merck on positive oncology data. This is going to be big and will take 4D valuation to the level they deserve. Not sure what this level is at present but those who are saying $2B+ may not be off the mark. 2. In almost an instance, the Nasdaq listing has effectively been pushed through, magic! 3. The costs and work associated with Nasdaq listing has been eliminated completely, magic! 4. 4D partnering an existing shell company (LOAC) can immediately commence marketing of LBPS prior to official listing approx. mid Jan 2021. On balance a very intelligent move. Onwards and upwards imho. | frrinvest | |
24/10/2020 09:35 | That is a great find showmethemoneyhoney0 | thresholdbypass | |
24/10/2020 09:24 | You never know! | showmethemoneyhoney01 | |
24/10/2020 08:53 | Is there an Arbitrage opportunity here??Potentially... | rastamouse | |
24/10/2020 08:35 | LOAC up 3.21% yesterday. Looks like it hasn’t gone unnoticed. | johnveals | |
24/10/2020 08:30 | Stig could you explain to a simpleton like me, why Loac is a cheap way into 4d please. | kangaman | |
24/10/2020 07:40 | https://twitter.com/ | rastamouse | |
23/10/2020 23:28 | You can but laoc on trading 212 | gooner1886 | |
23/10/2020 23:24 | Have had same problem trying to buy $LOAC It now represents a v.cheap way into DDDD I suspect US retail investors not woken up to this story yet... must be v.tightly held I see Goldmans on the shareholder list. V.good sign. | the stigologist | |
23/10/2020 22:19 | why magli? | dope007 | |
23/10/2020 21:13 | Cant buy Loac on ii on line so will check monday with Dealers. | magli | |
23/10/2020 20:16 | And maybe diagnostics | thresholdbypass | |
23/10/2020 20:11 | Vaccines for flu need to be updated regularly, costly bussiness, maybe HPV is an exception, I do not know, but really, treatments are the bees knees in terms of money | thresholdbypass | |
23/10/2020 20:06 | Few 100k plus trades through showing late. Some good money coming into 4D now. Holding for a rerate back to 160p plus. | con90210 | |
23/10/2020 19:43 | Well all those Pharma's getting paid £billions for the flu vaccine need not bother anymore because according to the WHO there hasn't been a single positive recorded flu specimen since ... strangely enough when Covid started and that's world-wide. Choose whatever region country or whole world you like - Nothing. | katsy | |
23/10/2020 19:21 | Well, if you read the story it says that Gardasil, Merck's human papillomavirus vaccine, had $3.7 billion in sales last year. Not too shabby imo. | someuwin | |
23/10/2020 19:07 | Thing is, vaccines are more or less the least interesting product in terms of revenue/profit of all medical products. Nice one off high profile turnover maybe, but high cost developement and very low margins in the long run. Not saying not worth it, but there are many other routes that are much more interesting | thresholdbypass | |
23/10/2020 19:00 | Interesting story about Merck playing Catch-Up in the Coronavirus vaccine chase... "The slower start has left Merck playing catch-up in the most important vaccine chase in modern history, a surprising position for one of the world's leading vaccine makers." Now, there's absolutely nothing in this story that suggests Merck are working with 4D on a Covid vaccine. But then if they were, no one would know until it was officially announced. All we do know is that Merck (MSD) are paying potentially $1bn+ to collaborate with 4D to develop LBP's as novel vaccines. We were told that they were targeting three 'undisclosed indications'. Now I know they started this collaboration before Covid broke out, but there's no reason they couldn't divert their research to Covid, After all this is 'the most important vaccine chase in modern history'. Just idle speculation on my part. But imagine the share price reaction if Merck / 4D were to announce that they had identified a possible candidate for an LBP Covid vaccine and were moving to a trial! After all, with this company anything is possible. | someuwin | |
23/10/2020 18:38 | Results Q3 Merck on Tuesday btw | thresholdbypass |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions